Advances in perinatal and neonatal medicine have significantly improved survival rates of preterm infants. This improvement has been associated with substantial risk of neurodevelopmental impairments and with increased number of infants with special health care needs. Cerebral palsy is the most well known and potentially most disabling motor abnormality associated with prematurity. There has been limited progress in understanding the causes of cerebral palsy and in developing primary prevention strategies. Several studies have summarized the experimental evidence that supports possible neuroprotective effects of magnesium. Five randomized controlled trials of antenatal magnesium sulfate found a trend of reduced risk of cerebral palsy in preterm infants. Three meta-analyses using the data from these five trials found that magnesium sulfate given to women at risk of premature birth significantly reduced the risk of cerebral palsy without increasing the risk of perinatal or infant death.
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The risk of serious medical disabilities such as CP, mental retardation and other developmental and behavioral disorders, as well as of other disabilities, such as blindness, hearing loss and epilepsy increases significantly with decreasing gestational age at birth. 2 The survival rate of very preterm infants who are at higher risk has continued to increase overtime due to advances in perinatal care, and whereas some data suggest that the rate of CP among survivors has declined, other data suggest that the rate is unchanged or even increasing. [2] [3] [4] The prevalence of CP ranges between 1.5 and 3.6 cases per 1,000 live births. 5 
Etiology of Cerebral Palsy
A full understanding of casual pathways and mechanisms leading to CP remains elusive in many cases at the present time. 1 In the pathophysiology of brain lesions associated with CP were described prenatal, perinatal and postnatal factors that include hypoxic-ischemic insults, maternal infection with production of proinflammatory cytokines, excessive glutamate release initiating the excitotoxic cascade, oxidative stress, growth factor deficiency, specific drugs and maternal stress. 6 It is believed that the timing of that insult is in the prenatal or perinatal period in about 70% of the cases in infants born preterm and 85% in those born at term, with only 10 to 28% cases of CP due to birth asphyxia. 7 Preterm delivery, low birth weight, intrauterine infection/inflammation, multiple gestation, maternal or fetal coagulation disorders, antepartum hemorrhage, and preeclampsia have all been associated with CP. 7, 8 Moreover, recent studies support the existence of genetic susceptibility factors. 6 Approximately one-third of cases of CP are associated with early preterm birth. 3 The risk of intraventricular hemorrhage increases with the lower the gestational age at birth. 9 The most prevalent pathological lesion seen in CP is periventricular white matter injury resulting from vulnerability of the immature preoligodendrocytes before 32 weeks of gestation. 5 Preterm birth is enormous public health concern since many of these preterm infants survive with neurobehavioral, cognitive and motor disabilities. 10 Both economically and emotionally, the burden of CP is enormous.
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Magnesium Sulfate: A Possible Role
An association between antenatal exposure to magnesium sulfate (MgSO 4 ) and a reduction in the risk of CP in infants born very low birth weights was first suggested by a casecontrol study published in 1995. 12 In this observational study children with CP were significantly less likely to have been MgSO 4 is commonly used worldwide in obstetric practice as an anticonvulsant for treatment of eclampsia and for seizure prophylaxis in pre-eclampsia, and is no longer recommended for tocolysis because it is ineffective. 13 The exact mechanism of action for the neuroprotective effect of MgSO 4 in preterm infants is not known. MgSO 4 has been proposed to act as a neuroprotectant through one or many of the following mechanisms: Reduction of inflammatory cytokines or free radicals produced during hypoxic-ischemic reperfusion, prevention of excitotoxic calcium-induced injury, membrane stabilization by preventing the membrane depolarization, inhibition of the glutamate receptors involved in injury to preoligodendrocytes, stabilization of fluctuations in blood pressure that occur in neonates, and an increase in cerebral blood flow. 5, 7, 14, 15 Other animal data suggest that MgSO 4 may serve an antiapoptotic role and prevent neuronal cell loss.
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During asphyxia, there is excessive release and reduced uptake of glutamate in the brain. Glutamate acts on the N-methyl-D-aspartate (NMDA) receptor, a postsynaptic ion channel, allowing excessive calcium influx into the neurons and inducing neuronal injury. 16 Fetal and newborn brains seem to be more susceptible to damage from glutamate release. 17 Magnesium is a naturally occurring NMDA receptor antagonist that blocks neuronal influx of calcium within the ion channels, preventing posthypoxic brain injury. 16 By its peripheral vasodilator effects, MgSO 4 can produce flushing, sweating and a sensation of warmth. Reported side effects include nausea, vomiting, headache, palpitations and rarely pulmonary edema. Administration above the recommended therapeutic levels can lead to respiratory depression, respiratory arrest, cardiac arrest and death. Hypermagnesemia at neonate can lead to hyporeflexia, poor sucking, and rarely, respiratory depression needing mechanical ventilation. 13, 17 Magnesium readily crosses the placenta, and can be detected in the fetal serum within 1 hour of maternal infusion, and in the amniotic fluid within 3 hours.
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Contraindications to MgSO 4 therapy are: Respiratory rate <16/min, absent patellar reflexes, urine output <100 ml during the previous 4 hours, renal failure, hypocalcemia. 
Randomized Controlled Trials
A number of randomized controlled trials were performed to assess the efficacy of MgSO 4 specifically for fetal neuroprotection in women at risk for preterm delivery. The characteristics of these trials are outlined in Table 1 The number of women at risk of preterm delivery less than 34 weeks of gestation who needed to be treated with magnesium rather than with placebo to prevent one case of CP in their children was 52 (95% CI: 31-154). There was no significant effect on pediatric mortality (RR: 1.01; 95% CI: 0.89-1.14). This last finding suggests the reduced risk of CP does not appear to be due to selective mortality of MgSO 4 -exposed infants. does not appear that treatment should be restricted to the latter. The findings of these three systematic reviews/metaanalyses are summarized in Table 2 .
Although minor maternal complications were more common associated with MgSO 4 therapy, there were no significant differences between magnesium and placebo control groups in severe maternal complications, including death, cardiac arrest and respiratory failure in trials or metaanalysis. 25 
International Guidelines
No standard approach has been established for use of MgSO 4 for neuroprotection. The American College of Obstetricians and Gynecologists encourages physicians electing to use MgSO 4 for fetal neuroprotection to develop specific guidelines around the issues of inclusion criteria, dosage, concurrent tocolysis, and monitoring in accordance with one of the larger trials. 25 The Antenatal Magnesium Sulfate for Neuroprotection Guideline Development Panel recommends MgSO 4 only at less than 30 weeks of gestation. They use a 4 gm loading intravenous dose (20-30 minutes) and a 1 gm/h maintenance dose, with no immediate repeat, until birth or for 24 hours. 26 The Society of Obstetricians and Gynecologists of Canada recommends that antenatal MgSO 4 administration should be considered for fetal neuroprotection when women present at < 31 + 6 weeks with imminent preterm birth (active labor with cervical dilatation > 4 cm, with or without preterm prelabor rupture of membranes) and/or planned preterm birth for fetal or maternal indications. They use a 4 gm intravenous loading dose, over 30 minutes, followed by a 1 gm/h maintenance infusion until birth.
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CONCLUSION
Preterm birth is a risk factor for CP, and the magnitude of the risk is inversely correlated with gestational age at birth. CP is a leading cause of chronic childhood disability, with profound medical, emotional, and economic consequences. CP is permanent and can result in severe sequelae for the infant, significantly affecting the family and the society. In order to reduce the impact of CP from very preterm birth, efforts must be focused on primary prevention.
Brain protection remains a challenge in infants who are born very preterm. MgSO 4 has been one of the rare pharmacologic interventions used in randomized control trials for its potential neuroprotective properties. The mechanisms by which magnesium might reduce or prevent neuronal damage have not been fully elucidated. While it is plausible that MgSO 4 could provide neuroprotection through mechanisms, such as reduced vascular instability and hypoxic damage, and reductions in cytokine/excitatory amino acid-induced damage, further study is needed to clarify its role in these processes. 15 Given the relative safety of MgSO 4 for the mother, the lack of evident risk regarding infant mortality, and the familiarity of most obstetricians with its use, MgSO 4 can be considered for neuroprophylaxis in the setting of preterm birth. The ideal candidate and the specific protocol should be decided upon at the institution level.
Comparisons between the published trials are made difficult by differences in inclusion criteria, population studied, magnesium sulfate regimens, gestational age and evaluated outcomes, and therefore, conclusions need to be interpreted cautiously. The appropriate total dosage, A reported economic analysis of magnesium neuroprophylaxis for women at risk for preterm birth less than 32 weeks of gestation concluded that MgSO 4 therapy is costeffective. 28 Encouraging results from systematic reviews and metaanalyses using several randomized controlled trials confirmed that administration of MgSO 4 improves the neurodevelopmental future of preterm infants.
These results suggest that antenatal MgSO 4 could be used for the primary prevention of CP in preterm infants. However, since CP is a result of multiple interacting risk factors rather than of a single cause, it is unlikely that antenatal MgSO 4 administration alone can prevent all cases of this illness in preterm infants.
